サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1412671

感染症ワクチン市場：製品別、感染症別、エンドユーザー別-2024-2030年の世界予測

Infectious Vaccines Market by Product (Preventive Vaccine, Therapeutic Vaccine), Infectious Disease (Allergy, Cervical Cancer, DTP), End User - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 183 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
感染症ワクチン市場：製品別、感染症別、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 183 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

感染症ワクチン市場規模は2023年に300億1,000万米ドルと推計され、2024年には318億3,000万米ドルに達し、CAGR 8.98%で2030年には548億3,000万米ドルに達すると予測されます。

感染症ワクチンの世界市場

主な市場の統計
基準年[2023］ 300億1,000万米ドル
予測年[2024］ 318億3,000万米ドル
予測年 [2030] 548億3,000万米ドル
CAGR（%） 8.98%
感染症ワクチン Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは感染症ワクチン市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、感染症ワクチン市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-感染症ワクチン市場の市場規模および予測は？

2-感染症ワクチン市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-感染症ワクチン市場における技術動向と規制の枠組みは？

4-感染症ワクチン市場における主要ベンダーの市場シェアは？

5-感染症ワクチン市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • HIV、がん、糖尿病などの慢性疾患の罹患率が高い
      • 政府は流行病を制御するための活動に重点を置いている
      • 健康に対する消費者の意識と支出の高まり
    • 抑制要因
      • ワクチン製造には高コストと長期のスケジュールが必要
    • 機会
      • 研究開発への官民セクターによる投資の増加
      • 小説感染症ワクチンのイントロダクション
    • 課題
      • ワクチンの副作用や有害事象の可能性
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 感染症ワクチン市場：製品別

  • 予防ワクチン
  • 治療用ワクチン

第7章 感染症ワクチン市場感染症別

  • アレルギー
  • 子宮頸がん
  • DTP
  • 肝炎
  • インフルエンザ
  • 髄膜炎菌
  • MMR
  • 肺炎球菌
  • ポリオ
  • ロタウイルス
  • 水痘

第8章 感染症ワクチン市場：エンドユーザー別

  • 大人
  • 小児科

第9章 南北アメリカの感染症ワクチン市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の感染症ワクチン市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの感染症ワクチン市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • Astellas Pharma, Inc.
    • AstraZeneca PLC
    • Bavarian Nordic A/S
    • Bharat Biotech
    • Biological E Ltd.
    • CSL Limited
    • DAIICHI SANKYO COMPANY, LIMITED
    • Emergent BioSolutions Inc.
    • GlaxoSmithKline PLC
    • Incepta Vaccine, Ltd.
    • Johnson and Johnson Services Inc.
    • Lonza Group AG
    • Merck & Co., Inc.
    • Mitsubishi Tanabe Pharma Corporation
    • Novartis International AG
    • Novavax, Inc.
    • Pfizer, Inc.
    • Sanofi SA
    • Serum Institute of India Pvt., Ltd
    • Sinovac Biotech Ltd.
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. INFECTIOUS VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. INFECTIOUS VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. INFECTIOUS VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. INFECTIOUS VACCINES MARKET DYNAMICS
  • FIGURE 7. INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2023 VS 2030 (%)
  • FIGURE 10. INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 12. INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. INFECTIOUS VACCINES MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. INFECTIOUS VACCINES MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. INFECTIOUS VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. INFECTIOUS VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 6. INFECTIOUS VACCINES MARKET SIZE, BY PREVENTIVE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. INFECTIOUS VACCINES MARKET SIZE, BY THERAPEUTIC VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 9. INFECTIOUS VACCINES MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. INFECTIOUS VACCINES MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. INFECTIOUS VACCINES MARKET SIZE, BY DTP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. INFECTIOUS VACCINES MARKET SIZE, BY MMR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. INFECTIOUS VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. INFECTIOUS VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. INFECTIOUS VACCINES MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. INFECTIOUS VACCINES MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 151. INFECTIOUS VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 152. INFECTIOUS VACCINES MARKET LICENSE & PRICING
目次
Product Code: MRR-ED54C46E8F81

[183 Pages Report] The Infectious Vaccines Market size was estimated at USD 30.01 billion in 2023 and expected to reach USD 31.83 billion in 2024, at a CAGR 8.98% to reach USD 54.83 billion by 2030.

Global Infectious Vaccines Market

KEY MARKET STATISTICS
Base Year [2023] USD 30.01 billion
Estimated Year [2024] USD 31.83 billion
Forecast Year [2030] USD 54.83 billion
CAGR (%) 8.98%
Infectious Vaccines Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Infectious Vaccines Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Infectious Vaccines Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Infectious Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma, Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech, Biological E Ltd., CSL Limited, DAIICHI SANKYO COMPANY, LIMITED, Emergent BioSolutions Inc., GlaxoSmithKline PLC, Incepta Vaccine, Ltd., Johnson and Johnson Services Inc., Lonza Group AG, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis International AG, Novavax, Inc., Pfizer, Inc., Sanofi SA, Serum Institute of India Pvt., Ltd, and Sinovac Biotech Ltd..

Market Segmentation & Coverage

This research report categorizes the Infectious Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Preventive Vaccine
    • Therapeutic Vaccine
  • Infectious Disease
    • Allergy
    • Cervical Cancer
    • DTP
    • Hepatitis
    • Influenza
    • Meningococcal
    • MMR
    • Pneumococcal
    • Polio
    • Rotavirus
    • Varicella
  • End User
    • Adults
    • Pediatrics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Infectious Vaccines Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Infectious Vaccines Market?

3. What are the technology trends and regulatory frameworks in the Infectious Vaccines Market?

4. What is the market share of the leading vendors in the Infectious Vaccines Market?

5. Which modes and strategic moves are suitable for entering the Infectious Vaccines Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Infectious Vaccines Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High prevalence of chronic diseases including HIV, cancer, diabetes
      • 5.1.1.2. Government focused activities to control epidemic diseases
      • 5.1.1.3. Rising consumer awareness and expenditure regarding health
    • 5.1.2. Restraints
      • 5.1.2.1. High costs and longer timelines required for vaccine production
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing investment by public & private sector for R&D endeavors
      • 5.1.3.2. Introduction of novel infectious vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Possibilities of vaccine side effects and adverse events
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Infectious Vaccines Market, by Product

  • 6.1. Introduction
  • 6.2. Preventive Vaccine
  • 6.3. Therapeutic Vaccine

7. Infectious Vaccines Market, by Infectious Disease

  • 7.1. Introduction
  • 7.2. Allergy
  • 7.3. Cervical Cancer
  • 7.4. DTP
  • 7.5. Hepatitis
  • 7.6. Influenza
  • 7.7. Meningococcal
  • 7.8. MMR
  • 7.9. Pneumococcal
  • 7.10. Polio
  • 7.11. Rotavirus
  • 7.12. Varicella

8. Infectious Vaccines Market, by End User

  • 8.1. Introduction
  • 8.2. Adults
  • 8.3. Pediatrics

9. Americas Infectious Vaccines Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Infectious Vaccines Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Infectious Vaccines Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. Astellas Pharma, Inc.
    • 13.1.3. AstraZeneca PLC
    • 13.1.4. Bavarian Nordic A/S
    • 13.1.5. Bharat Biotech
    • 13.1.6. Biological E Ltd.
    • 13.1.7. CSL Limited
    • 13.1.8. DAIICHI SANKYO COMPANY, LIMITED
    • 13.1.9. Emergent BioSolutions Inc.
    • 13.1.10. GlaxoSmithKline PLC
    • 13.1.11. Incepta Vaccine, Ltd.
    • 13.1.12. Johnson and Johnson Services Inc.
    • 13.1.13. Lonza Group AG
    • 13.1.14. Merck & Co., Inc.
    • 13.1.15. Mitsubishi Tanabe Pharma Corporation
    • 13.1.16. Novartis International AG
    • 13.1.17. Novavax, Inc.
    • 13.1.18. Pfizer, Inc.
    • 13.1.19. Sanofi SA
    • 13.1.20. Serum Institute of India Pvt., Ltd
    • 13.1.21. Sinovac Biotech Ltd.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing